Afuco™ Anti-Human IGF2 ADCC Therapeutic Antibody (DX-2647), ADCC Enhanced
Anti-IGF2 ADCC Enhanced Antibody (DX-2647) is an ADCC enhanced antibody produced by our Afuco™ platform. This is a human monoclonal antibody against insulin-like growth factor-II that blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. DX-2647 inhibited IGF-II and, to a lesser extent, IGF-I-induced receptor tyrosine phosphorylation, cellular proliferation, and both anchorage-dependent and anchorage-independent colony formation in various cell lines. In addition, DX-2647 slowed tumor progression in the Hep3B xenograft model, causing decreased tumoral CD31 staining as well as reduced IGF-IIE and IGF-IR phosphorylation levels. Therefore, DX-2647 offers an alternative approach to targeting IGF-IR, blocking IGF-II signaling through both IGF-IR and IR-A.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-372CL |
| Pricing | Inquiry |
| Host | Human |
| Target | IGF2 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at 4°C for up to 3 months. For longer term storage aliquot into small volumes and store at -20°C. |